Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Prince HM, Bashford J, Wall D, Rischin D, Parker N, Toner GC, Seymour JF, Blakey D, Haylock D, Simmons P, Francis P, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P.
Prince HM, et al. Among authors: bashford j.
Cytotherapy. 2002;4(2):137-45. doi: 10.1080/146532402317381848.
Cytotherapy. 2002.
PMID: 12006209
Clinical Trial.